Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal | The Manila Times
Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer. MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET5 and multi-time point SPECT6 imaging for patient selection using a 'theranostic” approach.
Ähnliche Seiten
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer | The Manila Times
https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-cancer/2385465
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/pr-newswire/ipax-2-study-of-tlx101-tx-in-first-line-glioblastoma-completes-enrolment-and-confirms-dosing/2346661ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/prostact-global-phase-3-part-1-data-presented-in-late-breaking-oral-session-at-asco-2026/2356288Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine | The Manila Times
https://www.manilatimes.net/2026/07/09/tmt-newswire/pr-newswire/groundbreaking-achievement-study-of-ensartinib-as-postoperative-adjuvant-therapy-published-in-the-new-england-journal-of-medicine/2381317Nexsphere-F™ Clinical Study Published in Radiology, Showing 57% Reduction in Knee Osteoarthritis Pain | The Manila Times
https://www.manilatimes.net/2026/07/06/tmt-newswire/pr-newswire/nexsphere-f-clinical-study-published-in-radiology-showing-57-reduction-in-knee-osteoarthritis-pain/2379105